Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Mouth Neoplasms × tozuleristide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Mouth Neoplasms 1

Interventions

Cisplatin 4 Radiotherapy 2 Paclitaxel 2 tozuleristide 1 pembrolizumab 1 niraparib 1 dostarlimab 1 dacomitinib 1 advexin 1 Taxes 1 Sirolimus 1 Pemetrexed 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 FPP(RGD)2 1 Chemoprevention 1 Amifostine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05316688 2026-02-25

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

University of Washington

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡